Video summary

Application of HSPCs in Cell Therapy - Session 1, Part 1

Main summary

Key takeaways

Educational

Main ideas / concepts covered

  • Course overview (Stem Cells on-demand; 5 sessions total)
    • Reviews hematopoiesis (blood formation) and hematological diseases
    • Covers HLA basics for transplantation
    • Discusses field considerations for improving hematopoietic cell therapy products
    • Explains workflow and compliance considerations for hematopoietic stem cell therapy products
    • Looks ahead to future directions in human PSC-derived hematopoietic cell therapy products
  • Session 1 structure
    • Part 1: Hematological disease and disease progression
    • Part 2: Hematopoietic stem cell therapy products

Hematopoiesis and how disease develops

Normal hematopoiesis

  • In human adults, blood formation (hematopoiesis) occurs in the bone marrow
  • It ensures an adequate supply of lineage-specific progenitor cells under normal conditions and during infection or injury

When hematopoietic control fails

  • Disruptions can lead to hematological diseases
  • Abnormal development causes too many or too few of the three mature blood cell types:
    • Red blood cells (oxygen transport)
    • White blood cells (immune defense against pathogens)
    • Platelets (implied role in coagulation)

Categories of hematopoietic diseases

  • Benign/non-cancerous disorders
    • Example: cytopenias (low RBCs, WBCs, or platelets)
  • Hematological malignancies (blood cancers)
    • Uncontrolled proliferation of abnormal blood cells
  • Inherited genetic mutation disorders
    • Mutations in hematopoietic stem cells (HSCs)

Disease progression concepts (disease states and trajectories)

1) Myeloproliferative neoplasms (MPNs)

  • Cause / origin (as described)
    • Driven by a somatic mutation in common myeloid progenitor cells
  • Effect
    • Mutated clone gains proliferative advantage
    • Leads to overproduction of combinations of:
      • granulocytes, monocytes, erythrocytes, and megakaryocytes
  • Examples and key clinical implications
    • Myelofibrosis
      • Bone marrow gradually replaced by fibrosis → eventual bone marrow failure
    • Polycythemia vera
      • Overproduction of red blood cells → hyperviscosity
      • Increased risk of thrombosis/clots and cardiovascular complications
    • Essential thrombocythemia
      • Overproduction of platelets → thrombotic or hemorrhagic events

2) Myelodysplastic syndromes (MDS)

  • Cause / origin (as described)
    • Arise from a small population of disease-initiating HSCs
  • Effect
    • Ineffective hematopoiesis, often:
      • refractory cytopenias
      • morphologic dysplasia
      • recurrent genetic abnormalities
    • Can progress to:
      • bone marrow failure
      • acute myeloid leukemia (AML)
  • Prognostic models
    • IPSS and revised IPSS (IPSS-R)
    • Risk assessed using clinical, morphologic, and cytogenetic features
    • Higher-risk MDS → greater likelihood of progression to AML and reduced overall survival
  • Example: refractory cytopenias
    • Refractory cytopenia with unilineage dysplasia (RCUD)
    • Examples:
      • refractory anemia
      • refractory neutropenia
      • refractory thrombocytopenia

3) Leukemia overview and classification

  • Definition
    • Cancer affecting white blood cells (leukocytes)
  • How leukemias are categorized
    • Lineage: lymphoid vs myeloid
    • Disease course: acute vs chronic
    • Origin
      • Myeloid leukemias: myeloid cells (bone marrow/blood)
      • Lymphoblastic leukemias: lymphocytes (lymphatic system; often lymph nodes)
  • Four main types mentioned
    • Acute myeloid leukemia (AML)
    • Chronic myeloid leukemia (CML)
    • Acute lymphoblastic leukemia (ALL)
    • Chronic lymphocytic leukemia (CLL)
  • Other (rarer) types mentioned
    • T-cell acute lymphoblastic leukemia
    • Hairy cell leukemia
    • T-cell large granular lymphocytic leukemia
  • Progression speed
    • Acute leukemias: develop rapidly
    • Chronic leukemias: develop slowly
  • Myeloma note
    • Multiple myeloma: malignant clonal plasma cells (from B cells)
    • Can crowd out healthy marrow cells → complications:
      • destructive bone lesions
      • kidney injury
      • anemia
      • hypercalcemia

Age, mutations, and clonal hematopoiesis

Increasing incidence over time

  • Leukemia incidence described as steadily increasing over ~30 years
  • Linked (as stated) to:
    • more somatic mutations with an aging population
    • resulting strong age-group correlation

Mutation burden in HSCs (as stated)

  • Each of 50 to 200,000 HSCs (born) can acquire about:
    • ~1 exonic mutation per decade (as presented)
  • By age 70, expected average:
    • ~70 mutations per gene in at least one HSC

Clonal expansion

  • Definition
    • HSCs produce daughter cells with the same mutation
    • These cells become genetically distinct from other blood cells

CHIP (Clonal hematopoiesis of indeterminate potential)

  • What it is
    • Clonal expansion where one or more somatic mutations exist
    • The clone expansion does not yet meet diagnostic criteria for a hematological malignancy
  • Epidemiology
    • Common and age-related
    • Prevalence increases significantly in individuals >60
  • Genes / pathways implicated (as described)
    • epigenetic regulation
    • RNA splicing
    • DNA repair
  • Associated health risks (key messages)
    • Increased risk of:
      • myeloid malignancies
      • myeloproliferative neoplasms (MPNs)
      • myelodysplastic syndromes
      • inherited bone marrow failure syndromes
    • May impact immune cell function, contributing to:
      • autoimmune diseases
    • Recently described association with cardiovascular disease
      • Nearly 4-fold increased risk with hypertension
      • Approximately 7-fold higher risk for cardiovascular disease when combined with hypertension (as stated)
  • Risk modifiers for clonal expansion and progression
    • Age
    • Inherited genetic variation
    • History of chemotherapy and radiation
  • CHIP treatment status (as stated)
    • No established therapies currently

Existing treatments and targeted therapy examples (MPN focus)

Traditional/standard approaches mentioned

  • Phlebotomy
    • Used to lower red blood cell counts (e.g., PV)
  • Hydroxyurea
    • Controls/inhibits cell growth

JAK2 and pathway targeting

  • JAK2 V617F mutation
    • Found in:
      • majority of polycythemia vera
      • more than half of myelofibrosis and essential thrombocythemia
  • Rationale
    • Indicates crucial role of JAK-STAT pathways in MPN development
  • Example therapy
    • JAK1/2 inhibitors (example given: ruxolitinib)
    • Success noted for:
      • reducing excess myeloid cell production
      • lowering inflammatory cytokine levels
      • improving MPN-related symptoms
  • Limitation
    • Limited impact on the MPN stem cell pool
  • Research direction
    • Combination therapies targeting downstream compensatory pathways, such as:
      • PI3 kinase
      • MAP kinase

Transplant mention in MPN context

  • Allogeneic hematopoietic stem cell transplant
    • Only high-risk myelofibrosis patients may be considered (as stated)
  • Lower-risk PV/ET
    • Typically treated with hydroxyurea and JAK2 inhibitors (as stated)

MDS low blood counts (treatment direction as described)

  • When low blood counts result from MDS or from chemotherapy/radiation/autoimmune conditions:
    • transfusion of healthy donor blood cells is described as traditional therapy
    • Autoimmune examples mentioned: lupus and rheumatoid arthritis

Inherited vs acquired blood disorders (high-level recap)

Inherited blood disorders

  • Caused by point mutations affecting:
    • HSCs or committed progenitors
  • Scale of diversity (as stated)
    • ~5,000 distinct diseases caused by alterations in >200 genes
    • Many are hemoglobinopathies
  • Examples given
    • bleeding disorders: hemophilia, von Willebrand disease
    • immunodeficiencies
    • anemias
    • metabolic diseases
  • Common treatments (as described)
    • pharmaceutical drugs to manage symptoms, control progression, or stimulate production
    • blood transfusions for missing/dysfunctional components (RBCs, platelets, plasma)

Allogeneic bone marrow transplantation (conceptual role)

  • Only currently available curative option for certain inherited disorders and malignancies (as stated)
  • Involves:
    • transplantation of HSCs from a matched donor
  • Major risks
    • donor immune cells attack host → rejection or graft-versus-host disease (GVHD)

Emerging strategy: autologous transplantation with gene editing

  • Promising, evolving strategy:
    • harvest patient stem cells
    • perform precise genetic editing to correct the defect
    • reinfuse edited cells
  • Goal: personalized and potentially curative therapies

HSCT (hematopoietic stem cell transplantation) and key steps

Standard role of HSCT (as described)

  • Present standard of care and established cure for:
    • severe hematological disorders
    • malignancies
    • immune deficiencies
  • Core idea:
    • replace diseased/dysfunctional bone marrow with healthy HSCs/progenitors

Conditioning regimen (method / process)

  • HSCT requires a preparative phase called conditioning
  • Conditioning typically uses:
    • high-intensity chemotherapy and/or total body irradiation
  • Purposes (as stated):
    • eradicate malignant cells
    • suppress host immune system
    • create space in marrow niche for engraftment and expansion

Risks

  • Conditioning is associated with:
    • significant toxicity
    • severe side effects
    • treatment-related mortality

HSCT types and sources

  • Allogeneic
    • cells from a matched donor
  • Autologous
    • cells from the patient
  • Donor sources (allogeneic)
    • umbilical cord blood
    • bone marrow
    • peripheral blood
  • Autologous main source
    • peripheral blood

HSCT success factors and immunological outcomes

Two critical success aspects

  1. Engraftment and regeneration
    • Transplanted HSCs rebuild the recipient’s blood-forming system
    • Durability of reconstitution affects long-term outcome and remission
  2. Immunological interplay
    • Donor immune cells vs recipient tissues
    • Generates both beneficial and harmful effects

Beneficial effect (allogeneic)

  • Graft-versus-leukemia (GVL)
    • Donor-derived T cells detect and destroy remaining cancer cells
    • Reduces relapse risk and helps eradicate disease

Harmful effects (allogeneic)

  • Graft-versus-host disease (GVHD)
    • Donor T cells recognize recipient cells as “non-self”
    • Attack healthy tissues across organs (skin, liver, GI tract)
    • Severity ranges from mild to life-threatening multi-organ failure
  • Total graft rejection
    • Recipient immune system rejects donor graft
    • Leads to failure of engraftment and additional intervention needs

Autologous vs allogeneic tradeoff (as stated)

  • Autologous HSCT
    • Uses patient’s own previously collected stem cells
    • Avoids GVHD and graft rejection (immunologically identical)
    • Limitation: long-term efficacy may be limited by residual disease and relapse (no GVL effect)
  • Allogeneic HSCT
    • Higher immune-mediated risks (GVHD/rejection)
    • May offer better long-term outcomes due to more durable anti-tumor effects (in some malignancies)

Advancements in HSCT over decades (method themes)

  • Improved HLA matching
    • Reduce risk of GVHD and rejection
  • Better immunosuppressive regimens
    • For GVHD prophylaxis and treatment
  • Novel conditioning regimens
    • Aimed at reducing transplant-related mortality
  • Strategies to enhance GVL
    • While mitigating GVHD
  • Historical shifts described:
    • 1980s: Increased transplants → research to reduce GVHD
      • included T-cell depletion
    • 1990s: Relapses after transplant (non-Hodgkin lymphoma and B-cell ALL)
      • led to donor lymphocyte infusion to improve T-cell reconstitution
      • intended to exploit beneficial graft-versus-leukemia effects

Link to adoptive T cell therapy

  • Insights into immune regulation/anti-tumor immunity supported development of:
    • adoptive T cell therapy
  • Focus described:
    • ex vivo expansion of:
      • patient (autologous) T cells, or
      • engineered T cells to recognize and eradicate malignant cells
  • Scope expansion:
    • initially hematological malignancies
    • now being explored for potential use in solid tumors

Transfusions vs cell transplantation (key distinctions)

Two main categories of hematopoietic cell therapies

  • HS cell transplant
    • Replaces diseased system with healthy stem/progenitor cells
  • Blood transfusions
    • Administration of mature blood cells to temporarily address deficiencies
    • Supportive therapy for many blood disorders
    • Also important during/around HSCT to replace cells lost due to conditioning and/or support donor-immune-related use cases

Risks / practical differences highlighted

  • Transfusions
    • Depend on voluntary blood donation
    • Risks include:
      • transfusion-transmitted infection
      • possible blood group incompatibilities
  • Stem cell transplants
    • Intended as a one-time long-term solution
    • Can potentially cure multiple blood disorders by replacing the patient’s blood-producing system

Forward-looking focus in the field (HSPCs as described)

  • Research aims to improve options and outcomes by:
    • ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs)
      • improve clinical outcomes
      • accelerate recovery after stem cell transplant
    • Using expanded HSPCs to manufacture blood components in lab settings
      • generate RBCs, platelets, and other components
      • intended to provide a more consistent, safer, and readily available supply of blood products

Methodology / instruction-style content (explicit steps and decision points)

HSCT conditioning phase (process elements)

  • Administer high-intensity chemotherapy and/or total body irradiation to:
    • eradicate malignant cells
    • suppress host immune system
    • create marrow niche space for donor/infused cells

HSCT immunological outcome management goals (strategy direction)

  • For allogeneic HSCT:
    • maximize GVL (anti-tumor)
    • minimize GVHD and rejection
  • Methods mentioned as research/clinical refinements:
    • refine HLA matching
    • use immunosuppressive regimens for prophylaxis/treatment
    • use conditioning regimens to reduce mortality
    • consider immune-modulating approaches (e.g., T-cell depletion, donor lymphocyte infusion) depending on relapse/GVHD balance

Autologous gene-edited concept (emerging workflow)

  • Harvest patient stem cells
  • Perform precise genetic editing to correct the disease-causing defect
  • Reinfuse edited cells
  • Goal: personalized potentially curative therapy

Speakers / sources featured (as referenced in the subtitles)

  • Dr. E. Donnall Thomas (named as documenting successful engraftment in 1957)
  • International Prognostic Scoring System (IPSS) (named source/tool for MDS risk)
  • Revised IPSS (IPSS-R) (named source/tool for MDS risk)
  • JAK kinase / JAK-STAT pathway (named biological pathway; no individual speaker)
  • ruxolitinib (named drug example)
  • hydroxyurea (named drug example)
  • ruxolitinib / PI3 kinase / MAP kinase (named therapeutic targets/pathways)
  • CHIP (acronym source; concept defined within lecture)
  • GVL (graft-versus-leukemia; acronym from lecture content)
  • GVHD (graft-versus-host disease; acronym from lecture content)
  • HSCT / HSPCs (acronyms from lecture content; no external person named)

(No distinct narrator name/host is provided in the subtitles.)

Original video